



Investor Information

Exentis Business Update

- ◆ **Successful start into 2025**
- ◆ **Several renowned US corporations acquired as customers**
- ◆ **Another two Exentis 3D production systems delivered**

Stetten, Switzerland, February 17, 2025 – Exentis Group AG, provider of the only 3D technology platform worldwide that enables industrial large-scale manufacturing, has successfully started into 2025. Since the beginning of the year, another two Exentis 3D production systems have been delivered. These systems will be used in the New Energy area for the industrial production of innovative components for fuel cells.

Exentis' business in the US, the world's most important market for industrial additive manufacturing solutions, continues to develop promisingly. Following the successful sale of 9 Exentis production systems to the US in the fourth quarter of 2024, additional orders from major industrial customers in various sectors have been acquired in the current year. These include two renowned global US corporations listed in the Dow Jones index.

As a next step, two Exentis Pharma production systems for the licensee Laxxon Medical will be delivered, one to Laxxon's development site in Germany and another large production system to a customer in Ohio, USA.

Exentis will publish its Annual Report 2024 in the second quarter of 2025 following the audit of the annual financial statements by the auditor BDO.

This year's Annual General Meeting of Exentis Group AG will take place on Friday, June 27, 2025, in the 3D Innovation Center at the corporate head office in Stetten, Aargau. Further details will be provided in the invitation to the Annual General Meeting at the beginning of June.

About Exentis

As a solution provider, Exentis has the only proprietary 3D technology platform worldwide that allows for industrial large-scale production. Industrialized Additive Manufacturing is universally applicable. For industrial or clean room applications. With free choice of materials, such as metals, ceramics, polymers, pharmaceutical or bio-printing products. The highly flexible 3D production technology combines rework-free component geometries with advantageous cost-benefit ratios. The cold printing process in use is sustainable and conserves materials as well as resources. Our customers, the Exentis 3D community members, can choose between exclusive in-house manufacturing under license agreements or having Exentis produce millions of applications for them as a contract manufacturer.

For further information please contact:

Benjamin del Fabro
Head of Investor Relations

+41 44 520 46 00
b.delfabro@exentis-group.com

Visit us also on our website at www.exentis-group.com.